Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14 by Hiroaki Kanemura, Masayuki Takeda, Shigeki Shimizu, Kazuhiko Nakagawa

Subjects: “…Capmatinib…”
Get full text

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis by Ibiayi Dagogo-Jack, MD, Lesli A. Kiedrowski, MS, MPH, Rebecca S. Heist, MD, MPH, Jessica J. Lin, MD, Catherine B. Meador, MD, PhD, Elizabeth A. Krueger, NP, Andrew Do, BS, Jennifer Peterson, BS, Lecia V. Sequist, MD, MPH, Justin F. Gainor, MD, Jochen K. Lennerz, MD, PhD, Subba R. Digumarthy, MD

Subjects: Get full text

HPLC with Fluorescence and Photodiode Array Detection for Quantifying Capmatinib in Biological Samples: Application to In Vivo and In Vitro Studies by Aref Zayed, Sana’a A. Jaber, Jomana Al Hroot, Sahar Hawamdeh, Nehad M. Ayoub, Nidal A. Qinna

Subjects: “…capmatinib…”
Get full text

Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature by Daniel S Lefler, Marni Brisson Tierno, Babar Bashir

Subjects: Get full text

Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Re... by Caio Abner Leite, Raíssa Pierri Carvalho, Felipe Marques da Costa, Augusto Kreling Medeiros, Fabio Augusto Schutz, William Nassib William, William Nassib William

Subjects: Get full text

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema by Kei Kunimasa, Takahisa Kawamura, Motohiro Tamiya, Takako Inoue, Hanako Kuhara, Kazumi Nishino, Toru Kumagai

Subjects: “…capmatinib…”
Get full text

Capmatinib suppresses LPS-induced interaction between HUVECs and THP-1 monocytes through suppression of inflammatory responses by Hyung Sub Park, A.M. Abd El-Aty, Ji Hoon Jeong, Taeseung Lee, Tae Woo Jung

Subjects: “…Capmatinib…”
Get full text

A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma by Armando Santoro, Eric Assenat, Thomas Yau, Jean-Pierre Delord, Michela Maur, Jennifer Knox, Stephane Cattan, Kyung-Hun Lee, Gianluca Del Conte, Christoph Springfeld, Elisa Leo, Alexandros Xyrafas, Lauren Fairchild, Feby Mardjuadi, Stephen L. Chan

Subjects: “…Capmatinib…”
Get full text

Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression by Elisa Carouge, Clémence Burnichon, Martin Figeac, Shéhérazade Sebda, Nathalie Vanpouille, Audrey Vinchent, Marie‐José Truong, Martine Duterque‐Coquillaud, David Tulasne, Anne Chotteau‐Lelièvre

Subjects: “…Capmatinib…”
Get full text

Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC by Yige Sun, Jie Yang, Yingbo Li, Jing Luo, Jiemei Sun, Daoshuang Li, Yuchen Wang, Kai Wang, Lili Yang, Lina Wu, Xilin Sun

Subjects: Get full text

Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib... by Siqi Xiang, Liang Zeng, Mingjun Xiang, Yongchang Zhang

Subjects: Get full text

Mining and evaluation of adverse event signals for capmatinib based on the FAERS database by Xinnan Chen, Ying Jiang, Haohao Zhu, Man Tian

Subjects: “…Capmatinib…”
Get full text

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib by Tan AC, Loh TJ, Kwang XL, Tan GS, Lim KH, Tan DSW

Subjects: “…capmatinib…”
Get full text

In vitro effectiveness of CB469, a MET tyrosine kinase inhibitor in MET-activated cancer cells by Ji Yeon Song, Hyunsook An, Soojeong Kim

Subjects: Get full text

Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin by Chien-Yu Lin, Sheng-Huan Wei, Yi-Lin Chen, Chung-Ta Lee, Shang-Yin Wu, Chung-Liang Ho, Dean C. Pavlick, Po-Lan Su, Chien-Chung Lin, Chien-Chung Lin, Chien-Chung Lin

Subjects: Get full text

Rare Synchronous Lung Cancers in a Nonsmoker with Epidermal Growth Factor Receptor and Mesenchymal-Epithelial Transition Alterations: A Case Report by Xavier Baer, Mathieu Chevallier, Juliana Rey Cobo, Jérôme Plojoux, Claudio De Vito, Alfredo Addeo

Subjects: Get full text

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation by Brazel D, Zhang S, Nagasaka M

Subjects: Get full text

A Rapid and Sensitive UPLC-MS/MS Method for Quantifying Capmatinib in Human Liver Microsomes: Evaluation of Metabolic Stability by In Silico and In Vitro Analysis by Mohamed W. Attwa, Ali S. Abdelhameed, Aishah M. Alsibaee, Adnan A. Kadi

Subjects: “…capmatinib…”
Get full text

Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy by Marc Zuckermann, Chen He, Jared Andrews, Aditi Bagchi, Roketa Sloan-Henry, Brandon Bianski, Jia Xie, Yingzhe Wang, Nathaniel Twarog, Arzu Onar-Thomas, Kati J. Ernst, Lei Yang, Yong Li, Xiaoyan Zhu, Jennifer K. Ocasio, Kaitlin M. Budd, James Dalton, Xiaoyu Li, Divyabharathi Chepyala, Junyuan Zhang, Ke Xu, Laura Hover, Jordan T. Roach, Kenneth Chun-Ho Chan, Nina Hofmann, Peter J. McKinnon, Stefan M. Pfister, Anang A. Shelat, Zoran Rankovic, Burgess B. Freeman, Jason Chiang, David T. W. Jones, Christopher L. Tinkle, Suzanne J. Baker

Subjects: Get full text

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges by Fujino T, Suda K, Mitsudomi T

Subjects: Get full text